Sort   by:  
 Page size 
TranscriptomicsGGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
Background: We have previously shown that the Gene expression Grade Index (GGI) was able to identify two subtypes of estrogen receptor (ER)-positive tumors that were associated with statistically distinct clinical outcomes in both untreated and tamoxifen-treated patients. Here, we aim to investigate...
ORGANISM(S): Homo sapiens 
2009-07-09 | E-GEOD-16391 | biostudies-arrayexpress
TranscriptomicsPrediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs.
Lymph node involvement is the most important prognostic factor in breast cancer, but little is known about the underlying molecular changes. First, to identify a molecular signature associated with nodal metastasis, gene expression analysis was performed on a homogeneous group of 96 primary breast t...
ORGANISM(S): Homo sapiens 
2011-02-04 | E-GEOD-23177 | biostudies-arrayexpress
UnknownThe Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.
Not available
S-EPMC2713270 | biostudies-literature
UnknownGGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
Not available
ORGANISM(S): Homo sapiens 
S-ECPF-GEOD-16391 | biostudies-other
UnknownSystematic benchmarking of single-cell ATAC-sequencing protocols.
Not available
S-EPMC11180611 | biostudies-literature
UnknownMicroRNA related polymorphisms and breast cancer risk.
Not available
S-EPMC4229095 | biostudies-literature
Unknown19p13.1 is a triple-negative-specific breast cancer susceptibility locus.
Not available
S-EPMC3319792 | biostudies-literature
UnknownLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.
Not available
S-EPMC3771688 | biostudies-literature
UnknownAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Not available
S-EPMC3235950 | biostudies-literature
UnknownLetrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Not available
S-EPMC2921823 | biostudies-literature
Sort   by:  
 Page size